Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y6TX
|
|||
| Drug Name |
PMID26560530-Compound-32
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
Aston University
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H29N2O6S+
|
|||
| Canonical SMILES |
C[S+](C)CC(=O)CCC(C(=O)O)NC(=O)C1CCCN1C(=O)OCC2=CC=CC=C2
|
|||
| InChI |
1S/C21H28N2O6S/c1-30(2)14-16(24)10-11-17(20(26)27)22-19(25)18-9-6-12-23(18)21(28)29-13-15-7-4-3-5-8-15/h3-5,7-8,17-18H,6,9-14H2,1-2H3,(H-,22,25,26,27)/p+1/t17-,18-/m0/s1
|
|||
| InChIKey |
SKEWALVSEUJDCH-ROUUACIJSA-O
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue transglutaminase (TG2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Tissue transglutaminase (TG2) | Target's Patent Info | [1] | |
| KEGG Pathway | Huntington's disease | |||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Thromboxane A2 receptor signaling | ||||
| Alpha9 beta1 integrin signaling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.